Bio-Techne (TECH) has entered into a partnership with genome engineering firm Kytopen to accelerate cell therapy manufacturing, the companies said Thursday.
The collaboration will focus on combining their technologies, TcBuster GMP non-viral genome engineering system and Flowfect Tx GMP cellular engineering platform, according to a joint statement.
Shares of Bio-Techne were up more than 2% in recent trading.
Price: 49.99, Change: +1.24, Percent Change: +2.54
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.